Clinical trials: Psoriasis
Psoriasis Vulgaris
Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris
To compare the results of vitamin D plus UVB in treatment of psoriasis vulgaris with the results of UVB alone to study the relation between serum vitamin D and PASI score before and after treatment.
- Trial name
- NCT03874975
- Testing
- oral vitamin D
- Volunteers
- 40 people
- Sponsor
- Assiut University
Autoimmune Diseases, Rheumatoid Arthritis (RA)
A Trial of Academic Detailing to Promote Prescribing of Biosimilars
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1.
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Psoriasis (PsO)
- Trial name
- NCT07221890
- Testing
- Offered an academic detailing session, Standard-of-care outreach from the insurance plan
- Where
- 2 sites in United States
- Volunteers
- 1,325 people
- Sponsor
- Brigham and Women's Hospital
Psoriatic Arthritis, Upadacitinib
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life.
- Conditions
- Psoriatic Arthritis, Upadacitinib, Interleukin-17 Inhibitors
- Trial name
- UVIPWP (NCT07386717)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Psoriasis Vulgaris
Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis
Psoriasis is a chronic inflammatory and proliferative papulosquamous skin disease of unknown cause,overexpression of Anti Microbial Peptides is characteristic of psoriasis.
- Trial name
- NCT03469219
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Assiut University
Arthritis, Rheumatoid, Colitis, Ulcerative
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
The purpose of this study is to learn about the safety of the safety of the study medicine called infliximab for the possible treatment of rheumatoid arthritis (RA), ulcerative colitis (UC, Crohn's disease, or psoriasis.
- Conditions
- Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis
- Trial name
- NCT05796245
- Where
- Japan
- Volunteers
- 2,207 people
- Sponsor
- Pfizer
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.
- Trial name
- NCT01090427
- Testing
- Ustekinumab - Half-Standard Dosage, Ustekinumab - Standard Dosage
- Where
- 50 sites in Belgium, Canada and 8 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Pediatric Psoriasis
Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis
Enbrel was first approved as new medicine on 06 Oct 2003 in Korea and the indication of Pediatric Psoriasis was approved on 23 Sep 2009.
- Trial name
- NCT01432249
- Testing
- Enbrel group
- Sponsor
- Pfizer
Arthritis, Rheumatoid, Crohn Disease
A Long-term Safety Study of Infliximab (Remicade)
This is a study evaluating the long-term safety of infliximab (Remicade)
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Trial name
- NCT00261976
- Testing
- Infliximab (Remicade)
- Where
- 205 sites in United States, Argentina and 17 more
- Volunteers
- 2,971 people
- Sponsor
- Centocor, Inc.
Psoriasis
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
Psoriasis is one of the commonest and most researched chronic immune-mediated inflammatory skin disorders that affects approximately 1-3% of the population worldwide and significantly impairs patients' quality of life.
- Trial name
- NCT06050330
- Testing
- skin biopsy
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sohag University
Psoriatic Arthritis
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients.
- Trial name
- NCT06586281
- Testing
- Guselkumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Arthritis, Psoriatic
Study Evaluating the Safety of Enbrel (Etanercept)
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
- Trial name
- NCT00683384
- Testing
- Etanercept (Enbrel)
- Where
- Philippines
- Volunteers
- 93 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Generalized Pustular Psoriasis, Erythrodermic Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Trial name
- NCT06295692
- Testing
- JNJ-77242113
- Where
- 12 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-LEAD (NCT06095115)
- Testing
- JNJ-77242113
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 684 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
Several studies have documented an essential role for interleukin-10 (IL-10) in preventing prolonged and exaggerated immune responses to antigens and irritants.
- Trial name
- NCT00001797
- Testing
- Recombinant human interleukin-10
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Dermatitis, Atopic, Dermatitis, Contact
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events.
- Conditions
- Dermatitis, Atopic, Dermatitis, Contact, Dermatitis, Seborrheic, Psoriasis
- Trial name
- NCT01011621
- Testing
- 0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream
- Volunteers
- 170 people
- Sponsor
- Mantecorp Industria Quimica e Farmaceutica Ltd.
Plaque Psoriasis, Biologic Agents
To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse
In recent years, an increasing number of patients who have experienced poor efficacy or adverse drug reactions using traditional treatment regimens have received biologic therapy and achieved satisfactory treatment results.
- Conditions
- Plaque Psoriasis, Biologic Agents, Relapse, Influence Factors
- Trial name
- NCT07730619
- Testing
- Diagnosis and Physical Examination of Psoriasis
- Where
- China
- Volunteers
- 140 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals